Stockscreener 앱 받기
29.65
0.07%
0.02
시간 외 거래:
30.15
0.50
+1.69%
전일 마감가:
$29.63
열려 있는:
$29.5
하루 거래량:
1.37M
Relative Volume:
0.63
시가총액:
$3.44B
수익:
-
순이익/손실:
$-472.34M
주가수익비율:
-7.1516
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
+1.44%
1개월 성능:
-2.05%
6개월 성능:
-16.99%
1년 성능:
+9.98%
1일 변동 폭
$29.00
$30.31
1주일 범위
$27.16
$30.31
52주 변동 폭
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.65 | 3.44B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
VKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
VKTX News | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Is Viking Therapeutics Stock Going to $100? - AOL.com
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance
VKTX Stock Price, Quote & Chart - ChartMill
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma
Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus
Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com
Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria
Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz
Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com
Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - PR Newswire
Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN
VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com
Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500
Viking Therapeutics, Inc. (VKTX) falls more steeply than broader market: What investors need to know - MSN
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven (VKTX) - Seeking Alpha
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Why (VKTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Current ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Asset turnover of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VT - TradingView
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
Viking Therapeutics, Inc. Revenue Breakdown – XETR:1VT - TradingView
Viking Therapeutics, Inc. Cash Flow – XETR:1VT - TradingView
Viking Therapeutics, Inc. Balance Sheet – XETR:1VT - TradingView
Viking Therapeutics, Inc. Statistics – XETR:1VT - TradingView
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Obesity Drug Progress Draws Investor Attention - simplywall.st
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
InvestingPro’s overvalued call on Viking Therapeutics saves investors 41% By Investing.com - Investing.com
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jan 05 '26 |
Sale |
32.90 |
57,661 |
1,896,969 |
189,891 |
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
1.27%
1.43%
자본화:
|
볼륨(24시간):